Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

February 14, 2023

Study Completion Date

February 14, 2023

Conditions
DM1Myotonic Dystrophy 1Myotonic DystrophyMyotonic Dystrophy Type 1 (DM1)Dystrophy MyotonicMyotonic DisordersSteinert DiseaseMyotonic Muscular Dystrophy
Interventions
DRUG

AOC 1001

AOC 1001 will be administered by intravenous (IV) infusion.

DRUG

Placebo

Placebo will be administered by intravenous (IV) infusion.

Trial Locations (8)

14642

University of Rochester Medical Center, Rochester

23298

Virginia Commonwealth University, Richmond

32608

University of Florida, Gainesville

43221

Ohio State University, Columbus

66205

Kansas University Medical Center, Kansas City

80045

University of Colorado, Denver

90095

University of California Los Angeles, Los Angeles

94304

Stanford University, Palo Alto

Sponsors
All Listed Sponsors
lead

Avidity Biosciences, Inc.

INDUSTRY

NCT05027269 - Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients | Biotech Hunter | Biotech Hunter